Citations

Clear

99 citation(s) found for "Son, Y".

Human iPSC models reveal APOE4-induced microglial remodeling and extracellular vesicle dysregulation in AD pathogenesis
Ikezu, Tsuneya , You, Yang , Nguyen, Son , Mann, Sean, Vadakattu, Prakruthi, Kanekiyo, Takahisa , Zhang, Zhengrong, Ray, Nibedita Basu, Tuck, Tony, TCW, Julia , Ikezu, Seiko , Gonzalez-Perez, Maria Paz , Ikezu, Tsuneya , Yang, You , Nguyen, Son , Goate, Alison , Karch, Celeste M. , Poon, Wayne W. , Shaffer, Scott A. , Duong, Angela , Kanekiyo, Takahisa , Goate, Alison M , Karch, Celeste M , Shaffer, Scott , Gonzalez-Perez, Maria Paz , Poon, Wayne W

Mayo Clinic

No container title available | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8594804/v1 | PMID 42818533 Get It

Abstract The apolipoprotein E ε4 ( APOE4 ) allele is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), yet the mechanistic underpinnings by which it alters human microglial function remain poorly understood. Here, we utilize CRISPR/Cas9-engineered isogenic human induced pluripotent stem cell-derived microglia-like cells (iMGs) expressing APOE3 or APOE4 to systematically interrogate genotype-dependent effects on microglial proteomes and their secreted extracellular vesicles (EVs) under basal and fibrillar amyloid-β (fAβ)-challenged conditions. Quantitative proteomics revealed that APOE4 iMGs exhibit downregulated RNA processing, impaired phagocytosis, and exacerbated pro-inflammatory signaling, particularly upon fAβ exposure. Functionally, APOE4 iMGs demonstrated increased NF-κB activation, enhanced neuronal apoptosis and tau pathology in 2D and 3D co-culture systems. Interestingly, APOE4 iMGs released greater amount of EVs enriched in proteasomal components over APOE3 iMG. Integrated proteomic analyses further highlighted APOE4 -specific selective packaging of EV cargo linked to neuron-glia communication, inflammatory signaling, and proteostasis dysregulation, suggesting a potent, non-cell-autonomous mechanism driving neuronal damage. Consistently, these APOE4 iMGEVs were preferentially internalized by neurons, leading to disrupted neuronal proteostasis, impaired neuronal firing, and increased tau phosphorylation, particularly under pathological stress. Notably, pharmacologic inhibition of NF-κB in APOE4 iMGs reduced EV cargo-loading of proteasomal molecules and mitigated iMGEV-driven neuronal dysfunction and tau pathology. These findings establish a mechanistic link between APOE4 , dysregulated microglial homeostasis, and microglial EV-mediated propagation of proteostatic dysfunction and neurodegeneration, advancing our understanding of how APOE4 contributes to AD pathogenesis.
Age‐specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta‐Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
Izmirly, Peter M. , Ferucci, Elizabeth D. , Hersh, Aimee O. , Son, Mary Beth, Lim, S. Sam , Crowson, Cynthia S., Duarte‐García, Alí , Buyon, Jill P., Gold, Heather T. , Dall'Era, Maria, Plantinga, Laura , Somers, Emily C., Parton, Hilary, Izmirly, Peter , Drenkard, Cristina , Duarte-García, Alí , Gold, Heather T , Katz, Patricia , Yazdany, Jinoos , Lim, S Sam , Ferucci, Elizabeth D , Son, Mary Beth F. , Crowson, Cynthia S. , Buyon, Jill P. , Dall’Era, Maria , Katz, Patricia , Yazdany, Jinoos , Somers, Emily C. , Parton, Hilary B.

Mayo Clinic

Arthritis & Rheumatology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/art.70306 | PMID 42635302 Get It

Objective Epidemiologic estimates for age of systemic lupus erythematosus (SLE) diagnosis are limited, particularly for men and racial and ethnic subpopulations in the United States. Leveraging the Centers for Disease Control and Prevention (CDC) National Lupus Registry network of population‐based SLE registries, meta‐analyses were performed estimating age‐specific incidence of SLE by sex, race, and ethnicity. Methods The CDC network of SLE registries includes five state‐based registries, plus a sixth Indian Health Service registry. Incidence periods spanned calendar years 2002‐2018. Registries provided age‐specific incidence of SLE, fulfilling the American College of Rheumatology (ACR) SLE classification criteria, per 100,000 person‐years, stratified by sex, race, and ethnicity for the meta‐analyses. Results Incidence rates among women were highest for those aged 30‐39 (12.7, 95%CI: 9.5‐16.8), while rates among men were highest for those aged 60‐69 (2.1, 95%CI: 1.3‐3.4). Black women aged 20‐39 had the highest SLE incidence rates (23.6, 95%CI: 20.7‐26.8). Among women diagnosed with SLE before age 20, incidence was highest among Asian (6.5, 95%CI: 2.8‐15.2) individuals. Among women diagnosed with SLE after age 60, incidence was highest among American Indian/Alaska Native (9.4, 95%CI: 3.4‐15.4) individuals. Weighted percentages show 10.0% of those with SLE were diagnosed before age 20, while 15.1% were diagnosed after age 60. The largest proportion of individuals with SLE, 22.1%, were diagnosed between 30‐39 years. Conclusions This study provides comprehensive sex‐ and race‐specific estimates of age at SLE diagnosis. The substantial later in life SLE incidence among men and disease burden in pediatric and older populations should raise awareness in considering SLE in the differential diagnosis in previously underrecognized groups.
Activation of Glucose-6-Phosphate Dehydrogenase Promotes Cardiomyocyte Cell Cycle
Li, Faqin , Son, Yura , Qiu, Huiliang , Li, Fan , Zhang, Andrew , Zhu, Wuqiang , Qiu, Hongyu , Zhu, Wuqiang

Mayo Clinic

Circulation | August 17, 2026 | Volume: 154 | Issue: 7 | Pages: 674-677

10.1161/circulationaha.125.076424 | PMID 42607118 Get It

Characteristics of Gender-Diverse Patients With Breast Cancer
Cortina, Chandler S., Brazauskas, Ruta , Flanagan, Meghan R., Dill, Ellen D., Joseph, Kathe-Ann P., Trifonov, Alexandr , Kim, Esther A. , Kantor, Olga, Barmettler, Gabi , Rosenberger, Laura H., Jordan, Sumanas W., Perez, Megan M. , Jimenez, Rachel B., Smart, Alicia , Walker, J C, Lautner, Meeghan A., Siegel, Emily L., Brabender, Danielle , Al-Hilli, Zahraa, Cassidy, Michael R., Weiss, Anna, McCaffrey, Rachel L., Lee, M Catherine, Kaoutzanis, Christodoulos, Nguyen, Khoa N., Son, Jennifer D., Williams, Austin D., Madrigrano, Andrea, McLaughlin, Sarah A., Stolley, Melinda, Cortina, Chandler S. , Flanagan, Meghan R. , Mukhtar, Rita A. , Kantor, Olga , Rezak, Kristen M. , Rosenberger, Laura H. , Jimenez, Rachel , Kopkash, Katherine A. , Hughes, Tasha M. , Walker, Jasmine C. , Lautner, Meeghan Ann, Siegel, Emily , Al‐Hilli, Zahraa , Cassidy, Michael Ryan , Weiss, Anna, McCaffrey, Rachel Louise , Kaoutzanis, Christodoulos , Son, Jennifer D. , Williams, Austin David , Petroll, Andrew E. , Stolley, Melinda R.

Mayo Clinic

JAMA Network Open | July 23, 2026 | Volume: 9 | Issue: 7 | Pages: e2624824

10.1001/jamanetworkopen.2026.24824 | PMID 42490110 Get It

Importance Limited granular data exist on breast cancer in transgender, nonbinary, and/or gender-diverse (TGD) individuals. Objective To describe patient demographic and tumor clinicopathological variables, clinically relevant risk factors, method of breast cancer detection, treatment characteristics, and locoregional outcomes and to estimate a 5-year breast cancer–specific survival (BCSS). Design, Setting, and Participants This cohort study obtained data on patients treated from 1990 to 2023 from 22 US academic medical centers using institutional databases, electronic medical records, and tumor registries. Included participants were TGD individuals 18 years or older with stage 0 to IV breast cancer. A comparative breast cancer cohort was selected from the 2016 to 2021 Surveillance, Epidemiology, and End Results Program (SEER) breast cancer dataset. Data were analyzed from January to October 2025. Exposure Breast cancer. Main Outcomes and Measures Estimated 5-year BCSS and locoregional recurrence rates. Wilcoxon rank sum and χ 2 tests were used to compare continuous and categorical variables. Kaplan-Meier analysis was used to estimate 5-year BCSS. Results A total of 112 TGD persons (median [IQR] age at diagnosis, 42.5 [36.5-51.0] years; 104 individuals [92.9%] were assigned female at birth) with breast cancer and 1 with bilateral disease were included in the analysis. Forty-three patients (38.4%) used gender-affirming hormone therapy before diagnosis. Among the entire cohort, 58 patients (51.8%) detected their own breast cancer, 68 (60.7%) had a familial breast cancer history, and 16 (14.3%) had a pathogenic germline variant. Tumors were predominantly hormone receptor positive (96 [85.7%]) and early stage (29 [25.7%] ductal carcinoma in situ [DCIS]; 51 [45.1%] stage I). The TGD cohort, compared with patients with breast cancer in the SEER dataset (N = 480 915), was younger (median [IQR] age, 42.5 [36.5-51.0] years vs 62.0 [52.0-72.0] years), had a higher proportion of persons assigned male at birth (8 [7.1%] vs 3522 [0.7%]), more often had progesterone receptor–positive disease (89 [79.5%] vs 335 491 [69.8%]), and presented with earlier-stage disease (eg, DCIS: 29 [25.9%] vs 79 604 [16.6%]). With a median (IQR) follow-up time for the TGD cohort of 38 (24-74) months, 5-year BCSS was favorable at 96.2% (95% CI, 85.3%-99.0%). Conclusions and Relevance This cohort study of TGD patients with breast cancer found that this population was young and often detected their own tumors via self-examination, suggesting opportunities to improve early detection through screening for individuals at elevated risk. Although short-term BCSS appeared favorable, prospective research is essential to define evidence-based guidelines and elucidate long-term outcomes.
The cloudy, dark, and sunny aspects of a dangerous and uncertain entity: Moderate traumatic brain injury
Godoy, Daniel Agustín , Rubiano, Andres Mariano, Llompart-Pou, Juan Antonio, Bárcena, Jon Pérez, Rabinstein, Alejandro, Llompart‐Pou, Juan Antonio , Rabinstein, Alejandro A.

Mayo Clinic

Journal of Neurosciences in Rural Practice | July 9, 2026 | Volume: 17 | Issue: No issue available | Pages: S26-S35

10.25259/jnrp_429_2025 Get It

Moderate traumatic brain injury (TBI) is a prevalent entity with a wide, dynamic, and heterogeneous injury spectrum. It has its own characteristics. However, it does not receive enough attention, as evidenced by the scarce representation in the literature and the absence of specific guidelines. Its changing epidemiological profile allows us to predict an increase in its incidence in the future, especially in the fragile population. Moderate TBI is not adequately categorized, and the risk of neuroworsening is elevated. The mortality of moderate TBI is not negligible and its functional outcomes are poor. Non-invasive neuromonitoring tools may have a key role in the initial evaluation and categorization of moderate TBI. Moderate TBI has cloudy, dark, and sunny aspects. To analyze these aspects and to propose management strategies constitute the main objective of this narrative review.
Assessment of psychological and physiological responses to auditory and visual stimuli during recovery from acute stress induction
Snyder, Eric M. , Son, Young Joo , Byun, Kunjoon , Snyder, Eric M , Li, Linhao, West, Colin P. , Mazurek, Kevin A.

Mayo Clinic

Physiology International | June 23, 2026 | Volume: 113 | Issue: 2 | Pages: 277-298

10.1556/2060.2026.00801 | PMID 42334880 Get It

Abstract Workplace stress is one of the main sources of stress for adults, although physiological and cognitive factors may impact each person's stress response. Numerous studies have shown heart rate, heart rate variability, neural activity, and cognitive performance are affected by stress. Additionally, visual and auditory stimuli in one's environment have been shown to affect individuals' reaction to stressful events. To our knowledge, few studies have examined how each of these physiological and cognitive measures relate to one's perception of stress, the ability to recover from stress, and what environmental factors may help with stress recovery. Here, 80 healthy adults performed a laboratory-controlled stress induction task where they experienced and recovered from an acute psychological stressor (Trier Social Stress Test, TSST, using verbal math skills and a public presentation that was videotaped). Throughout the assessment, heart rate, heart rate variability, and neural activity were measured using wearable devices to assess changes before, during, and after the stressor. Additionally, participants were assessed their perceived stress levels at specific times throughout the assessment. After the psychological stressor, participants were randomly assigned to one of four recovery conditions within a multisensory relaxation room: Control (C), Auditory Only (A), Visual Only (V), or Combined Auditory and Visual (AV). During the stressor, anxiety, heart rate, and beta EEG power increased and high-frequency power and heart rate variability decreased, confirming participants reactivity to the stressor ( P < 0.01 for all vs. baseline). Only the V and AV conditions led to notable reductions in anxiety (15 and 17%, respectively) vs. the C condition, but these did not reach statistical significance. There was no difference between V and AV, suggesting a stronger impact of V. We observed no differences between conditions during recovery for HR and HRV. Overall, these findings suggest the visual features of the relaxation room impacted self-reported anxiety, however physiological and neurological effects did not demonstrate a statistically meaningful response.
Tumefactive Demyelination at Multiple Sclerosis Onset Associates With Less Severe Long-term Disability (P4-19.006)
Neyal, Nur , Atkinson, E. C., Tarlton, Caitlin, Schwarz, Christopher, Decker, Paul, Kosel, Matthew, Son, Jiye , Keegan, Mark , Kantarci, Kejal, Kantarci, Orhun, Tobin, W., Aboseif, Albert , Atkinson, Elizabeth, Jackson-Tarlton, Caitlin S. , Schwarz, Christopher, Kosel, Matthew , Kantarci, Kejal , Kantarci, O, Zeydan, Burcu

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217162 Get It

Cervical Spinal Cord Atrophy in Multiple Sclerosis: Age, Sex, and Hormonal Status (P11-18.005)
Neyal, Nur , Son, Jiye , Schwarz, Christopher, Atkinson, Elizabeth, Morrison, Holly, Kantarci, Kejal, Flanagan, Eoin , Port, John, Kantarci, OH , Schwarz, Christopher, Nathoo, Nabeela , Kantarci, Kejal , Flanagan, Eoin P. , Port, John D. , Kantarci, Orhun H. , Zeydan, Burcu

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215592 Get It

A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.
Ailawadhi, Sikander, Musuraca, Gerardo, Jurczak, Wojciech, Gutierrez, Antonio, Иванов, В В , Misyurina, Elena, Наилевна, Хусаинова Гульнара, Tumyan, Gayane, Visentin, Andrea, Tani, Monica , Tomuleasa, Ciprian, Mikuskova, Eva, Yang, Dajun, Zhai, Yifan, Davids, Matthew S. , Ailawadhi, Sikander , Musuraca, Gerardo , Jurczak, Wojciech , Šimkovič, Martin , Malek, Sami N. , Nikitin, Eugene A. , Misyurina, Elena N , Khusainova, Gulnara N. , Tumyan, Gayane Sergeevna , Tomowiak, Cécile , Dû, Katell Le , Visentin, Andrea , Tomuleasa, Ciprian , Yang, Dajun, Zhai, Yifan

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps7101 Get It

TPS7101 Background: Patients with high-risk CLL/SLL not achieving a complete response (CR) after ≥ 12 months of BTK inhibitor (BTKi) monotherapy remain at risk for early progression due to residual disease and BTKi resistance. A BCL-2 inhibitor (BCL-2i) introduces a complementary, BCR-independent apoptotic mechanism that may deepen responses and prolong progression-free survival (PFS). Lisaftoclax, a selective oral BCL-2i with a short half-life (4-6 h), enables once-daily dosing and is approved in China as second-line CLL therapy. Lisaftoclax monotherapy has demonstrated overall response rates (ORRs) of 67% in relapsed/refractory CLL and 62.5% in BTKi-refractory disease, including del(17p)/ TP53 -mutated cases. Lisaftoclax combined with acalabrutinib achieved ORRs >97% with favorable tolerability. This study evaluates whether lisaftoclax plus BTKi (acalabrutinib, zanubrutinib, or ibrutinib) improves PFS and/or overall survival (OS) (vs continued BTKi monotherapy) in patients with CLL/SLL and residual disease after prolonged BTKi treatment. Methods: This study will enroll approximately 440 patients randomly allocated to receive lisaftoclax plus BTKi or BTKi alone. Eligible patients have CLL/SLL and, after ≥12 months of BTKi monotherapy (lines 1-3), have achieved neither CR nor progressive disease (PD). Randomization is stratified by del(17p)/ TP53 status. Key inclusion criteria include age ≥18 years, ECOG PS 0-2, and residual disease with either high-risk features (del(17p)/ TP53 mutation, unmutated IGHV , or complex karyotype [≥5 abnormalities]), or measurable residual disease with lymph nodes ≥2.5 cm in the absence of high-risk features. Exclusion criteria include prior BCL-2i therapy or Richter transformation. Patients in the investigational arm will undergo a 5-day oral lisaftoclax ramp-up to 400 mg once daily plus physician's choice of BTKi in 28-day cycles until progression or toxicity. Control patients continue their current BTKi monotherapy. Safety and disease assessments (CT/MRI) will occur regularly. The primary endpoint is PFS by independent review committee (iwCLL 2018); key secondary endpoint OS; and other secondary endpoints, PFS by investigator, ORR, duration of response, MRD negativity, and safety. Enrollment is ongoing across 126 sites in 18 countries (ClinicalTrials.gov ID: NCT06104566). Clinical trial information: NCT06104566 .